Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Date of authorisation: 24/05/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Date of authorisation: 24/05/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Imcivree, setmelanotide, Date of authorisation: 16/07/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Imcivree, setmelanotide, Date of authorisation: 16/07/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Avonex, interferon beta-1a, Date of authorisation: 13/03/1997, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Avonex, interferon beta-1a, Date of authorisation: 13/03/1997, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Pomalidomide Zentiva, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pomalidomide Zentiva, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Date of authorisation: 23/07/2012, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Date of authorisation: 23/07/2012, Revision: 36, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness